Strengthen your HTA application with RWE

Learn how to demonstrate drug effectiveness using RWE

12 Mar 2024

or

26 Sep 2024

On location

English

6,500 DKK ex VAT

(app. 874 EUR ex VAT)

50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary


How do you compare medicines in the best and most comprehensive way?

In addition to traditional clinical trials, Real World Evidence (RWE) has become a central basis for such comparators.

Scientific evidence based on data collected from sources other than traditional clinical trials, e.g. electronic health records, has become decisive when the effectiveness and safety of medicinal products is assessed, e.g. in connection with applications to the Medicines Council.

Methodologically, making comparisons between drugs, however, can be a challenging task. First, it is crucial to choose the appropriate method for the research question and the characteristics of the data being analysed. Second, it is important to consider the limitations and assumptions of each method to ensure that the analysis is conducted and interpreted correctly. Thus, insight into the RWE methodology used is essential.

This course gives you an overview of different statistical approaches for making effectiveness comparisons between drugs. This includes both how to make direct and indirect comparisons of effectiveness of treatment options in real-world settings, and how to create synthetic control arms.


Keywords

  • Market access
  • Real World Evidence (RWE)
  • Statistical analysis
  • Evidence generation
  • HTA evaluations

Save information for later
Read more

Course leader & lecturers

  • Klaus Kaae Andersen
    Course leader
    Director & Senior Statistician
    Omicron ApS
  • Christian Dehlendorff
    Lecturer
    Biostatistical Chief Consultant
    Medicinrådet
See all

Is this course for you?

This course is for health economists, statisticians, and others working with HTA applications and generation of RWE.

What you will learn

  1. How real-world data (RWD) can be used in comparison of the effectiveness of drugs.
  2. Common epidemiological designs used to generate RWE for comparative studies.
  3. Common methods used for making direct comparisons and interpretation of effects.
  4. Methods used for indirect treatment comparisons, pitfalls, and interpretation.

What your company will get

  1. An employee who knows how to generate direct and indirect comparisons of drugs using real world data.
  2. An employee who can choose the right RWE method for the specific purpose and set up the right experimental design.
  3. An employee who can advise colleagues on opportunities and limitations of RWE.

Course calendar

Choose your starting date
Starting 12 Mar 2024
Starting 26 Sep 2024
12 Mar 2024 9:00-16:00
  1. How can RWE be used in HTA applications?
  2. Building an RWE portfolio to support HTA applications
  3. Reproducibility and tips for reporting
  4. Indirect comparisons
  5. RWE in HTA applications for rare diseases

    Practical information

    Registration

    Registration deadline
    5 Mar 2024
    Atrium
    Lersø Parkallé 101
    2100 København Ø
    Register
    12 Mar
    26 Sep 2024 9:00-16:00
    1. How can RWE be used in HTA applications?
    2. Building an RWE portfolio to support HTA applications
    3. Reproducibility and tips for reporting
    4. Indirect comparisons
    5. RWE in HTA applications for rare diseases

      Practical information

      Registration

      Registration deadline
      19 Sep 2024
      Atrium
      Lersø Parkallé 101
      2100 København Ø
      Register
      26 Sep
      Sometimes things change. This is the expected programme.

      Course information

      Prerequisites

      Either statistical experience or pharma experience or both.

      Examination

      Not relevant. 

      This course is a part of a diploma

      Diploma in Market Access

      Our Diploma in Market Access provides you with in-depth knowledge of the Danish healthcare system and its funding models and stakeholders. Raise your skill level in areas such as public affairs, stakeholder management and health economics by attending the four courses

      Read more

      Course leader

      Klaus Kaae Andersen
      Director & Senior Statistician
      Omicron ApS

      Lecturers

      Klaus Kaae Andersen
      Director & Senior Statistician
      Omicron ApS
      Christian Dehlendorff
      Biostatistical Chief Consultant
      Medicinrådet

      You may also be interested in these courses

      Want to know more, or need help?

      Contact Client Manager Ida Salicath at +45 39 15 09 46